Drug Profile

SIG 1451

Alternative Names: SIG1451

Latest Information Update: 28 Mar 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Signum Biosciences
Class Nonsteroidal anti-inflammatories; Small molecules
Mechanism of Action G protein-coupled receptor modulators; Signal transduction pathway inhibitors; Toll-like receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Mar 2021 No recent reports of development identified for preclinical development in Atopic-dermatitis in USA (Topical)
15 Feb 2017 Preclinical trials in Atopic dermatitis in USA (Topical) (Signum Biosciences pipeline, February 2016)
15 Feb 2017 Signum Biosciences receives SBIR phase IIB grant from NIAID for SIG 1451 development in Atopic dermatitis

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com